ATE485296T1 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit - Google Patents
(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeitInfo
- Publication number
- ATE485296T1 ATE485296T1 AT04752844T AT04752844T ATE485296T1 AT E485296 T1 ATE485296 T1 AT E485296T1 AT 04752844 T AT04752844 T AT 04752844T AT 04752844 T AT04752844 T AT 04752844T AT E485296 T1 ATE485296 T1 AT E485296T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridinyl
- dichloro
- analgesic effectiveness
- analgesic
- effectiveness
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title 1
- MBQYQLWSBRANKQ-IMTBSYHQSA-N (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane Chemical compound N1=C(Cl)C(Cl)=CC(N2C[C@H]3NC[C@H]3C2)=C1 MBQYQLWSBRANKQ-IMTBSYHQSA-N 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/445,555 US20040242641A1 (en) | 2003-05-27 | 2003-05-27 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| PCT/US2004/015905 WO2004106342A1 (en) | 2003-05-27 | 2004-05-20 | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485296T1 true ATE485296T1 (de) | 2010-11-15 |
Family
ID=33450880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04752844T ATE485296T1 (de) | 2003-05-27 | 2004-05-20 | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20040242641A1 (de) |
| EP (1) | EP1626973B1 (de) |
| JP (1) | JP4716999B2 (de) |
| KR (2) | KR101238281B1 (de) |
| CN (1) | CN1826344B (de) |
| AT (1) | ATE485296T1 (de) |
| AU (1) | AU2004243270B2 (de) |
| BR (1) | BRPI0410808A (de) |
| CA (1) | CA2526530C (de) |
| CY (1) | CY1111946T1 (de) |
| DE (1) | DE602004029671D1 (de) |
| DK (1) | DK1626973T3 (de) |
| ES (1) | ES2352199T3 (de) |
| MX (1) | MXPA05012738A (de) |
| NZ (2) | NZ543615A (de) |
| PL (1) | PL1626973T3 (de) |
| PT (1) | PT1626973E (de) |
| SI (1) | SI1626973T1 (de) |
| TW (1) | TWI332502B (de) |
| WO (1) | WO2004106342A1 (de) |
| ZA (1) | ZA200509601B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004083388A2 (en) * | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| US20050261348A1 (en) * | 2004-05-21 | 2005-11-24 | Buckley Michael J | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| US7354937B2 (en) * | 2004-05-21 | 2008-04-08 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| US8222278B2 (en) * | 2008-06-03 | 2012-07-17 | Abbott Laboratories | Treatment of attention-deficit/hyperactivity disorder |
| ME02437B (de) | 2009-10-23 | 2016-09-20 | Janssen Pharmaceutica Nv | Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren |
| JP5847087B2 (ja) * | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| EP2525797A1 (de) * | 2010-01-20 | 2012-11-28 | Abbott Laboratories | Verfahren zur behandlung von schmerz |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| EA201891930A1 (ru) | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Способы лечения депрессии с использованием антагонистов орексиновых рецепторов-2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| EP1147112B1 (de) * | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden |
| JP2002543070A (ja) * | 1999-04-26 | 2002-12-17 | ニューロサーチ、アクティーゼルスカブ | ヘテロアリールジアザシクロアルカン類、その製造方法及びその使用方法 |
| BR0007229A (pt) * | 1999-05-21 | 2002-09-10 | Abbott Lab | Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
-
2003
- 2003-05-27 US US10/445,555 patent/US20040242641A1/en not_active Abandoned
-
2004
- 2004-05-20 PT PT04752844T patent/PT1626973E/pt unknown
- 2004-05-20 KR KR1020127001475A patent/KR101238281B1/ko not_active Expired - Fee Related
- 2004-05-20 BR BRPI0410808-6A patent/BRPI0410808A/pt not_active IP Right Cessation
- 2004-05-20 NZ NZ543615A patent/NZ543615A/xx not_active IP Right Cessation
- 2004-05-20 CA CA2526530A patent/CA2526530C/en not_active Expired - Fee Related
- 2004-05-20 CN CN2004800213271A patent/CN1826344B/zh not_active Expired - Fee Related
- 2004-05-20 NZ NZ588123A patent/NZ588123A/en not_active IP Right Cessation
- 2004-05-20 ES ES04752844T patent/ES2352199T3/es not_active Expired - Lifetime
- 2004-05-20 DK DK04752844.3T patent/DK1626973T3/da active
- 2004-05-20 AT AT04752844T patent/ATE485296T1/de active
- 2004-05-20 AU AU2004243270A patent/AU2004243270B2/en not_active Ceased
- 2004-05-20 JP JP2006533261A patent/JP4716999B2/ja not_active Expired - Fee Related
- 2004-05-20 KR KR1020057022595A patent/KR20060015738A/ko not_active Abandoned
- 2004-05-20 PL PL04752844T patent/PL1626973T3/pl unknown
- 2004-05-20 DE DE602004029671T patent/DE602004029671D1/de not_active Expired - Lifetime
- 2004-05-20 EP EP04752844A patent/EP1626973B1/de not_active Expired - Lifetime
- 2004-05-20 SI SI200431546T patent/SI1626973T1/sl unknown
- 2004-05-20 WO PCT/US2004/015905 patent/WO2004106342A1/en not_active Ceased
- 2004-05-20 MX MXPA05012738A patent/MXPA05012738A/es active IP Right Grant
- 2004-05-26 TW TW093114944A patent/TWI332502B/zh not_active IP Right Cessation
-
2005
- 2005-11-28 ZA ZA200509601A patent/ZA200509601B/en unknown
-
2011
- 2011-01-11 CY CY20111100032T patent/CY1111946T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004029671D1 (de) | 2010-12-02 |
| CA2526530A1 (en) | 2004-12-09 |
| EP1626973A1 (de) | 2006-02-22 |
| KR20060015738A (ko) | 2006-02-20 |
| WO2004106342A1 (en) | 2004-12-09 |
| NZ588123A (en) | 2012-04-27 |
| CA2526530C (en) | 2013-01-08 |
| NZ543615A (en) | 2009-04-30 |
| CN1826344A (zh) | 2006-08-30 |
| ES2352199T3 (es) | 2011-02-16 |
| BRPI0410808A (pt) | 2006-06-27 |
| TWI332502B (en) | 2010-11-01 |
| PL1626973T3 (pl) | 2011-04-29 |
| HK1092135A1 (en) | 2007-02-02 |
| KR101238281B1 (ko) | 2013-03-04 |
| PT1626973E (pt) | 2010-12-31 |
| ZA200509601B (en) | 2006-10-25 |
| CN1826344B (zh) | 2013-03-06 |
| JP4716999B2 (ja) | 2011-07-06 |
| CY1111946T1 (el) | 2015-11-04 |
| SI1626973T1 (sl) | 2011-01-31 |
| EP1626973B1 (de) | 2010-10-20 |
| DK1626973T3 (da) | 2011-01-10 |
| TW200510420A (en) | 2005-03-16 |
| KR20120014235A (ko) | 2012-02-16 |
| AU2004243270B2 (en) | 2009-12-17 |
| JP2007500220A (ja) | 2007-01-11 |
| MXPA05012738A (es) | 2006-02-22 |
| US20040242641A1 (en) | 2004-12-02 |
| AU2004243270A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111946T1 (el) | To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας | |
| MXPA02012681A (es) | Compuestos de sales de ditosilato de quinazolina. | |
| MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
| WO2002066500A3 (de) | ANTAGONISTEN FÜR Α4β7-INTEGRIN | |
| WO2005023302A3 (en) | Anti-cd20 therapy of ocular disorders | |
| SE9802208D0 (sv) | Novel compounds | |
| DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
| WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| ATE286883T1 (de) | Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität | |
| AU2002332488A8 (en) | R-bambuterol, its preparation and therapeutic uses | |
| EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
| ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
| SE9802209D0 (sv) | Novel compounds | |
| AU4910500A (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
| TW200616631A (en) | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane | |
| WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1626973 Country of ref document: EP |